131 related articles for article (PubMed ID: 29296784)
1. High proportions of PD-1
Hollander P; Kamper P; Smedby KE; Enblad G; Ludvigsen M; Mortensen J; Amini RM; Hamilton-Dutoit S; d'Amore F; Molin D; Glimelius I
Blood Adv; 2017 Aug; 1(18):1427-1439. PubMed ID: 29296784
[TBL] [Abstract][Full Text] [Related]
2. Programmed death 1 expression in the peritumoral microenvironment is associated with a poorer prognosis in classical Hodgkin lymphoma.
Koh YW; Jeon YK; Yoon DH; Suh C; Huh J
Tumour Biol; 2016 Jun; 37(6):7507-14. PubMed ID: 26678894
[TBL] [Abstract][Full Text] [Related]
3. Prognostic Impact of Tumor-Associated Macrophages on Survival Is Checkpoint Dependent in Classical Hodgkin Lymphoma.
Karihtala K; Leivonen SK; Brück O; Karjalainen-Lindsberg ML; Mustjoki S; Pellinen T; Leppä S
Cancers (Basel); 2020 Apr; 12(4):. PubMed ID: 32260340
[TBL] [Abstract][Full Text] [Related]
4. Programmed death-1 ligands PD-L1 and PD-L2 show distinctive and restricted patterns of expression in lymphoma subtypes.
Panjwani PK; Charu V; DeLisser M; Molina-Kirsch H; Natkunam Y; Zhao S
Hum Pathol; 2018 Jan; 71():91-99. PubMed ID: 29122656
[TBL] [Abstract][Full Text] [Related]
5. Expression of PD-1 and PD-L1 increase in consecutive biopsies in patients with classical Hodgkin lymphoma.
Hollander P; Amini RM; Ginman B; Molin D; Enblad G; Glimelius I
PLoS One; 2018; 13(9):e0204870. PubMed ID: 30261066
[TBL] [Abstract][Full Text] [Related]
6. Checkpoint CD47 expression in classical Hodgkin lymphoma.
Gholiha AR; Hollander P; Löf L; Glimelius I; Hedstrom G; Molin D; Hjalgrim H; Smedby KE; Hashemi J; Amini RM; Enblad G
Br J Haematol; 2022 Jun; 197(5):580-589. PubMed ID: 35301709
[TBL] [Abstract][Full Text] [Related]
7. GLUT1 as a Prognostic Factor for Classical Hodgkin's Lymphoma: Correlation with PD-L1 and PD-L2 Expression.
Koh YW; Han JH; Park SY; Yoon DH; Suh C; Huh J
J Pathol Transl Med; 2017 Mar; 51(2):152-158. PubMed ID: 28219001
[TBL] [Abstract][Full Text] [Related]
8. Revisiting IL-6 expression in the tumor microenvironment of classical Hodgkin lymphoma.
Gholiha AR; Hollander P; Glimelius I; Hedstrom G; Molin D; Hjalgrim H; Smedby KE; Hashemi J; Amini RM; Enblad G
Blood Adv; 2021 Mar; 5(6):1671-1681. PubMed ID: 33720338
[TBL] [Abstract][Full Text] [Related]
9. Programmed death-1 (PD-1), programmed death-ligand 1 (PD-L1), and EBV-encoded RNA (EBER) expression in Hodgkin lymphoma.
Paydas S; Bağır E; Seydaoglu G; Ercolak V; Ergin M
Ann Hematol; 2015 Sep; 94(9):1545-52. PubMed ID: 26004934
[TBL] [Abstract][Full Text] [Related]
10. An anergic immune signature in the tumor microenvironment of classical Hodgkin lymphoma is associated with inferior outcome.
Hollander P; Rostgaard K; Smedby KE; Molin D; Loskog A; de Nully Brown P; Enblad G; Amini RM; Hjalgrim H; Glimelius I
Eur J Haematol; 2018 Jan; 100(1):88-97. PubMed ID: 29064587
[TBL] [Abstract][Full Text] [Related]
11. Expression of programmed cell death ligand 1 (PD-L1) in advanced stage EBV-associated extranodal NK/T cell lymphoma is associated with better prognosis.
Kim WY; Jung HY; Nam SJ; Kim TM; Heo DS; Kim CW; Jeon YK
Virchows Arch; 2016 Nov; 469(5):581-590. PubMed ID: 27595782
[TBL] [Abstract][Full Text] [Related]
12. PD-L1 expression correlates with VEGF and microvessel density in patients with uniformly treated classical Hodgkin lymphoma.
Koh YW; Han JH; Yoon DH; Suh C; Huh J
Ann Hematol; 2017 Nov; 96(11):1883-1890. PubMed ID: 28842748
[TBL] [Abstract][Full Text] [Related]
13. Whole slide imaging of tumour microenvironment in classical Hodgkin's lymphoma: development of a clinical prediction model based on programmed death-ligand 1 and tumorous Reed-Sternberg cells.
Santisteban Espejo A; Bernal-Florindo I; Montero-Pavon P; Perez-Requena J; Atienza-Cuevas L; Villalba-Fernandez A; Garcia-Rojo M
J Clin Pathol; 2023 Nov; ():. PubMed ID: 37977655
[TBL] [Abstract][Full Text] [Related]
14. PD-L1 Immunohistochemistry Highlights Bone Marrow Involvement by Classic Hodgkin Lymphoma in Staging Biopsies: Implications for Diagnosis and Tumor Microenvironment Alterations.
Xing W; Mai N; Dresser K; Chen BJ
Appl Immunohistochem Mol Morphol; 2019; 27(5):356-363. PubMed ID: 29271790
[TBL] [Abstract][Full Text] [Related]
15. Programmed cell death 1 expression is associated with inferior survival in patients with primary central nervous system lymphoma.
Cho H; Kim SH; Kim SJ; Chang JH; Yang WI; Suh CO; Kim YR; Jang JE; Cheong JW; Min YH; Kim JS
Oncotarget; 2017 Oct; 8(50):87317-87328. PubMed ID: 29152083
[TBL] [Abstract][Full Text] [Related]
16. Prognostic Implications of Tumor-Infiltrating Lymphocytes in Association With Programmed Death Ligand 1 Expression in Early-Stage Breast Cancer.
Park IH; Kong SY; Ro JY; Kwon Y; Kang JH; Mo HJ; Jung SY; Lee S; Lee KS; Kang HS; Lee E; Joo J; Ro J
Clin Breast Cancer; 2016 Feb; 16(1):51-8. PubMed ID: 26364145
[TBL] [Abstract][Full Text] [Related]
17. PD-L1 Status in Refractory Lymphomas.
Vranic S; Ghosh N; Kimbrough J; Bilalovic N; Bender R; Arguello D; Veloso Y; Dizdarevic A; Gatalica Z
PLoS One; 2016; 11(11):e0166266. PubMed ID: 27861596
[TBL] [Abstract][Full Text] [Related]
18. The Association Between PD-L1 Expression and the Clinical Outcomes to Vascular Endothelial Growth Factor-Targeted Therapy in Patients With Metastatic Clear Cell Renal Cell Carcinoma.
Shin SJ; Jeon YK; Cho YM; Lee JL; Chung DH; Park JY; Go H
Oncologist; 2015 Nov; 20(11):1253-60. PubMed ID: 26424759
[TBL] [Abstract][Full Text] [Related]
19. Checkpoint Inhibition: Programmed Cell Death 1 and Programmed Cell Death 1 Ligand Inhibitors in Hodgkin Lymphoma.
Villasboas JC; Ansell S
Cancer J; 2016; 22(1):17-22. PubMed ID: 26841012
[TBL] [Abstract][Full Text] [Related]
20. PD-L1 is upregulated by EBV-driven LMP1 through NF-κB pathway and correlates with poor prognosis in natural killer/T-cell lymphoma.
Bi XW; Wang H; Zhang WW; Wang JH; Liu WJ; Xia ZJ; Huang HQ; Jiang WQ; Zhang YJ; Wang L
J Hematol Oncol; 2016 Oct; 9(1):109. PubMed ID: 27737703
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]